High-dose methylprednisolone and tocilizumab improve survival of patients with high-risk pediatric acute necrotizing encephalopathy
In low- to moderate-risk patients, the 20- and 30-mg/kg/day MP regimens were effective. In high-risk patients with ANE, high-dose MP (30 mg/kg/day), particularly when combined with tocilizumab, may improve survival and possibly long-term neurological recovery. These findings support the use of a severity-based immunotherapy strategy for pediatric patients with ANE.
Authors
- Chaonan Fan (ORCID: https://orcid.org/0009-0009-0096-0996)
- Yiyang Mao
- Kechun Li (ORCID: https://orcid.org/0000-0003-1611-0450)
- Gang Liu (ORCID: https://orcid.org/0000-0002-5180-3765)
- Fei Li (ORCID: https://orcid.org/0000-0001-6457-321X)
- Quan Wang (ORCID: https://orcid.org/0000-0002-7056-0519)
- Yingchao Liu (ORCID: https://orcid.org/0000-0002-1854-8432)
- Zheng Li (ORCID: https://orcid.org/0000-0001-7840-8303)
- Suyun Qian
- Lijuan Wang (ORCID: https://orcid.org/0009-0004-0505-6174)
Institutions
- Capital Medical University (CN)
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- Clinical and Experimental Pediatrics
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3345/cep.2025.01431
- Citations
- 1
- Primary Topic
- Infectious Encephalopathies and Encephalitis
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Capital Medical University
- Beijing Nova Program
- Beijing Children's Hospital, Capital Medical University